Zelig Tx is developing therapeutic solutions aimed at curing severe allergies. The company focuses on creating next‑generation treatments that target the underlying immune response, offering a potential long‑term remedy for patients with life‑threatening allergic conditions. Their approach leverages advanced biotechnology to deliver durable allergy relief.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with severe, high‑risk allergies have limited treatment options that only provide temporary symptom relief and often require ongoing medication, leading to reduced quality of life and risk of life‑threatening reactions.
Solution
Zelig Tx is developing disease‑modifying therapies aimed at providing long‑term relief or cure for severe allergic conditions. The company leverages advanced immunological research to create treatments that target the underlying mechanisms of allergy, rather than merely managing symptoms. By focusing on durable immune tolerance, Zelig Tx seeks to reduce the frequency of acute allergic episodes and the dependence on chronic medication. Ongoing preclinical and clinical programs are designed to address the most dangerous allergy phenotypes, with the goal of delivering safe, effective, and lasting therapeutic options to patients.
Target Audience
Primary customers are patients with severe, high‑risk allergies and healthcare providers (allergists, immunologists, and specialty clinics) seeking curative treatment options.
Features
- Proprietary platform for inducing durable immune tolerance to allergen-specific IgE responses
- Preclinical pipelines targeting multiple high‑risk allergy indications (e.g., food, insect‑venom, drug allergies)
- Integration of biomarker‑driven patient selection to enhance efficacy and safety
- Scalable biologic manufacturing process optimized for rapid clinical development
- Regulatory‑focused development strategy to accelerate path to market approval